Bacteriophage therapy in the era of antimicrobial resistance: clinical evidence, translational challenges, and emerging regulatory frameworks (2020–2026)
Aug 2026· Exploration of Medicine· Vol 7· 1 citation· 66 references
TL;DR
Routine clinical adoption of phage therapy will ultimately depend on outcomes of adequately powered confirmatory trials, alongside resolution of manufacturing, regulatory, and standardization challenges.
Abstract
Antimicrobial resistance has intensified the search for alternatives to conventional antibiotics, particularly against multidrug-resistant bacterial pathogens that increasingly compromise treatment outcomes in hospitals and community settings. This narrative review examines bacteriophage therapy as an alternative for combating multidrug-resistant bacteria. Recent literature is discussed thematically, with emphasis on original studies, clinical datasets, translational experiments, and regulatory documents. The current evidence base consists predominantly of compassionate-use reports, small cohorts, and early-phase trials, including CRISPR-enhanced and inhaled phage platforms, which report safety observations, compartment-specific responses, and microbiome effects in individual studies. Mechanistic considerations discussed in the review include route-specific delivery, phage–host ecological interactions, resistance trade-offs, and phage–antibiotic synergy. While microbiological and clinical responses have been reported in individual studies, no confirmatory randomized trial has demonstrated clinical efficacy for any phage therapy indication. Manufacturing, standardization, and regulatory pathways for scaled deployment also remain unresolved. Regulatory developments in Europe, the United Kingdom, the United States, and Australia remain heterogeneous and predominantly access-based or compassionate-use-based rather than approval-based. Specific technical challenges include incomplete standardization of susceptibility testing and the need for robust monitoring of immune neutralization, endotoxin burden, and long-term ecological effects. Routine clinical adoption of phage therapy will ultimately depend on outcomes of adequately powered confirmatory trials, alongside resolution of manufacturing, regulatory, and standardization challenges.
This review systematically analyzes major challenges restricting clinical application, such as standardized production, quality control, pharmacokinetic characterization, rapid pathogen identification, and regulatory adaptation, as well as the limited performance of fixed phage cocktails against genetically heterogeneo...
It is suggested that standardized, optimized bacteriophages may match the efficacy and biosafety of antibiotics, potentially enhancing their effectiveness in combination therapies.
Natália Chomová, G. Žoldák, D. Mudroňová· Veterinary research communic...· 0 citations
This review summarizes the current evidence on non-antibiotic therapeutics including bacteriophages, antimicrobial peptides, anti-virulence agents, monoclonal antibodies, microbiome-based therapies, CRISPR-Cas systems, nanoparticles, photodynamic therapy, repurposed non-antibiotic drugs and combination strategies.
B. Ganesan, A. Mishra, D. Hota et al.· Expert Review of Clinical Ph...· 0 citations
Pseudomonas aeruginosa is one of the World Health Organization's (WHO) priority pathogens requiring urgent intervention because of its remarkable ability to develop antimicrobial resistance. The rapid emergence and global dissemination of multidrug-resistant P. aeruginosa have made the treatment of these infections inc...
Ahmed Elfadadny, W. Nageeb, Rokaia F. Ragab et al.· Biomedicine & pharmacotherap...· 0 citations
The rapid emergence of antimicrobial resistance poses a serious challenge to both human and veterinary medicine highlighting the urgent need to develop alternative antimicrobial strategies. Phage therapy has regained attention as a promising approach. However, its application in veterinary practice remains relatively l...
Shang-Le Feng, Shi-Yu Xie, Fang-Jing He et al.· The Veterinary Journal· 0 citations
The analysis indicates that phage therapy shows promising results, particularly for treating multidrug-resistant bacterial infections, and offers a powerful alternative to traditional antimicrobials due to their specificity and environmental friendliness.
Seda Özdikmenli Tepeli, K. Selvi· Aksaray University Journal o...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.